Cresset Biomolecular Discovery Ltd forms a lead-finding collaboration with Pharmagene
Cresset BioMolecular Discovery Ltd (Cresset BMD) has announced that it has entered into a collaboration to find novel leads against one of Pharmagene's new drug discovery targets. Cresset will use its proprietary computational Field technology to generate electrostatic and surface-property molecular Fields for known active compounds against Pharmagene's target and use these to create templates to identify novel, diverse series of active compounds with drug-like characteristics.
Financial details of the collaboration were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.